Rhythm Pharma Q3 revenue $33.3M (+14% seq); FDA Priority Review for label expansion to age 2

RHYTHM PHARMACEUTICALS, INC.

2024-Q3 EPS reported -$3.62 revenue$88,296,000

IMCIVREE net revenue $33.3M (Q3 2024), up 48% YoY from $22.5M; US sales $23.3M (+8% seq), ex-US $10.0M (+35% seq).
Net loss $(45.0)M ($(0.73)/share) vs $(44.2)M ($(0.76)/share) in Q3 2023; cash $298.4M at Sep 30, 2024.
FDA accepted sNDA for Priority Review to treat children as young as 2 years; PDUFA date Dec 26, 2024.
Phase 3 hypothalamic obesity trial top-line data on track for 1H 2025; early-access French data showed 12.8% BMI reduction at 3 months.
FY 2024 non-GAAP operating expense guidance narrowed to $245-255M from $250-270M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.